Cost study of metal stent placement vs single-dose brachytherapy in the palliative treatment of oesophageal cancer
- PMID: 15150566
- PMCID: PMC2409487
- DOI: 10.1038/sj.bjc.6601815
Cost study of metal stent placement vs single-dose brachytherapy in the palliative treatment of oesophageal cancer
Abstract
Self-expanding metal stent placement and single-dose brachytherapy are commonly used for the palliation of oesophageal obstruction due to inoperable oesophagogastric cancer. We randomised 209 patients to the placement of an Ultraflex stent (n=108) or single-dose brachytherapy (12 Gy, n=101). Cost comparisons included comprehensive data of hospital costs, diagnostic interventions and extramural care. We acquired detailed information on health care consumption from a case record form and from monthly home visits by a specialised nurse. The initial costs of stent placement were higher than the costs of brachytherapy (1500 euro vs 570 euro; P<0.001). Total medical costs were, however, similar (stent 11 195 euro vs brachytherapy 10 078 euro, P>0.20). Total hospital stay during follow-up was 11.5 days after stent placement vs 12.4 days after brachytherapy, which was responsible for the high intramural costs in both treatment groups (stent 6512 euro vs brachytherapy 7982 euro, P>0.20). Costs for medical procedures during follow-up were higher after stent placement (stent 249 euro vs brachytherapy 168 euro, P=0.002), while the costs of extramural care were similar (1278 euro vs 1046 euro, P>0.20). In conclusion, there are only small differences between the total medical costs of both palliative treatment modalities, despite the fact that the initial costs of stent placement are much higher than those of brachytherapy. Therefore, cost considerations should not play an important role in decision making on the appropriate palliative treatment strategy for patients with malignant dysphagia.
Similar articles
-
[Palliative treatment of esophageal cancer with dysphagia: more favourable outcome from single-dose internal brachytherapy than from the placement of a self-expanding stent; a multicenter randomised study].Ned Tijdschr Geneeskd. 2005 Dec 10;149(50):2800-6. Ned Tijdschr Geneeskd. 2005. PMID: 16385833 Clinical Trial. Dutch.
-
Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial.Lancet. 2004 Oct 23-29;364(9444):1497-504. doi: 10.1016/S0140-6736(04)17272-3. Lancet. 2004. PMID: 15500894 Clinical Trial.
-
Health economic evaluation of stent or endoluminal brachytherapy as a palliative strategy in patients with incurable cancer of the oesophagus or gastro-oesophageal junction: results of a randomized clinical trial.Eur J Gastroenterol Hepatol. 2005 Dec;17(12):1369-77. doi: 10.1097/00042737-200512000-00017. Eur J Gastroenterol Hepatol. 2005. PMID: 16292092 Clinical Trial.
-
Palliation of dysphagia.Best Pract Res Clin Gastroenterol. 2018 Oct-Dec;36-37:97-103. doi: 10.1016/j.bpg.2018.11.010. Epub 2018 Nov 22. Best Pract Res Clin Gastroenterol. 2018. PMID: 30551864 Review.
-
[Palliative treatment in patients with oesophagus carcinoma].Ned Tijdschr Geneeskd. 2005 Dec 10;149(50):2775-82. Ned Tijdschr Geneeskd. 2005. PMID: 16385829 Review. Dutch.
Cited by
-
A cost and benefit study of esophagectomy for patients with esophageal cancer.J Gastrointest Surg. 2009 Oct;13(10):1806-12. doi: 10.1007/s11605-009-0965-9. Epub 2009 Jul 28. J Gastrointest Surg. 2009. PMID: 19636642
-
Comparative study of self-expanding metal stent and intraluminal radioactive stent for inoperable esophageal squamous cell carcinoma.World J Surg Oncol. 2016 Jan 22;14(1):18. doi: 10.1186/s12957-016-0768-x. World J Surg Oncol. 2016. PMID: 26800661 Free PMC article. Clinical Trial.
-
Optimal Management of Dysphagia in Patients with Inoperable Esophageal Cancer: Current Perspectives.Cancer Manag Res. 2022 Nov 23;14:3281-3291. doi: 10.2147/CMAR.S362666. eCollection 2022. Cancer Manag Res. 2022. PMID: 36448034 Free PMC article. Review.
-
Cost-effectiveness of palliation of unresectable esophageal cancer.Dig Dis Sci. 2008 Dec;53(12):3103-11. doi: 10.1007/s10620-008-0302-2. Epub 2008 Jun 4. Dig Dis Sci. 2008. PMID: 18523886
References
-
- Adam A, Ellul J, Watkinson A, Tan BS, Morgan R, Sanunders M, Mason RC (1997) Palliation of inoperable oesophageal carcinoma: a prospective randomised trial of laser therapy and stent placement. Radiology 202: 344–348 - PubMed
-
- Bartelsman JF, Bruno MJ, Jensema AJ, Haringsma J, Reeders JW, Tytgat GN (2000) Palliation of patients with esophagogastric neoplasms by insertion of a covered expandable modified Gianturco-Z endoprosthesis: experiences in 153 patients. Gastrointest Endosc 51: 134–138 - PubMed
-
- Botterweck AA, Schouten LJ, Volovics A, Dorant E, van den Brandt PA (2000) Trends in incidence of adenocarcinoma of the esophagus and gastric cardia in ten European countries. Int J Epidemiol 29: 645–654 - PubMed
-
- Brewster AE, Davidson SE, Makin WP, Stout R, Burt PA. (1995) Intraluminal brachytherapy using the high dose rate microSelectrion in the palliation of carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 7: 102–105 - PubMed
-
- Dallal HJ, Smith GD, Grieve DC, Ghosh S, Penman ID, Palmer KR (2001) A randomized trial of thermal ablative therapy versus expandable metal stents in the palliative treatment of patients with esophageal carcinoma. Gastrointest Endosc 54: 549–557 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical